A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Feb 2018
At a glance
- Drugs Copanlisib (Primary)
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Registrational
- Acronyms CHRONOS-2
- Sponsors Bayer
- 25 Jan 2018 Planned End Date changed from 7 May 2018 to 21 Nov 2019.
- 25 Jan 2018 Planned primary completion date changed from 7 May 2018 to 7 Nov 2018.
- 07 Jun 2017 Planned End Date changed from 31 Oct 2019 to 7 May 2018.